The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland

Lausanne, Switzerland, Wednesday Oct 16 As a world leading company within diarrhoeal vaccine development, Scandinavian Biopharma is regularly invited to participate in global conferences that bring together renowned researchers and decision makers from the pharmaceutical industry, international authorities and global health organisations. Scandinavian Biopharma’s vaccine ETVAX® is rated as the most advanced vaccine in the […]

Scandinavian Biopharma awarded and qualified “Gazelle Company” by Dagens Industri

We are excited to share that we have been awarded the honourable title Gazelle company by Dagens Industri, DI. This means that we belong to the fastest growing companies in Sweden that are financially profitable with strong financial position. DI Gasell is a prize that is awarded by the financial newspaper Dagens Industri to Sweden’s […]

We are one of the Biotech Company of the Year finalists at the 2019 European Lifestars Awards!

Scandinavian Biopharma has been nominated to “Biotech company of the year” for the “European Lifestars Awards 2019” by @LSXLeaders. The award recognises a European biotech company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community. Find out more […]

Scandinavian Biopharma is launching an updated brand identity

We have refreshed our brand identity for it to better align with our business model, core values and vision. The whole team has been engaged in the rebranding process and together we have formed the basis of Scandinavian Biopharma’s new graphical design that is being launched today.

Scandinavian Biopharma announces great progress in the development of ETVAX® as well as a strong organic growth for the distribution business

Scandinavian Biopharma can look back on a very successful 2018! The company was granted 7,4 million Euro from the European and Developing Countries Clinical Trials Partnership (EDCTP) for testing the protective efficacy of the ETEC vaccine candidate ETVAX® in children below five years of age in Low- and Middle-Income Countries. The distribution business achieved a […]



Go to MyNewsdesk

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.